Armata Pharmaceuticals (ARMP) Net Income (2013 - 2026)
Armata Pharmaceuticals (ARMP) posted Net Income of -$67.2 million for Q1 2026, down 260.09% sequentially from -$18.7 million in Q4 2025, and down 469.68% YoY from $18.2 million in Q1 2025.
Armata Pharmaceuticals (ARMP) Net Income (2013 - 2026) Analysis & Trends
Armata Pharmaceuticals has reported Net Income for 14 years, with the latest figure at -$67.2 million in Q1 2026.
- Quarterly Net Income fell 469.68% year-over-year to -$67.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$167.1 million (up 10.43% YoY) and the FY2025 annual result came in at -$134.4 million, down 6.12% from the prior year.
- Net Income eased to -$67.2 million in Q1 2026 per ARMP's latest filing, from -$18.7 million in the prior quarter.
- Over five years, Net Income peaked at -$10.0 million in Q3 2022 and troughed at -$81.3 million in Q2 2024.
- A 5-year average of -$27.2 million and a median of -$13.5 million in 2024 frame the typical range for Net Income.
- The sharpest annual moves came in 2024 and 2025: Net Income slumped 561.76% in 2024, then jumped 84.68% in 2025.
- Over 5 years, Net Income stood at -$10.3 million in 2022, then retreated by 6.26% to -$11.0 million in 2023, then plunged by 60.05% to -$17.5 million in 2024, then declined by 6.35% to -$18.7 million in 2025, then sank by 260.09% to -$67.2 million in 2026.
- According to Business Quant data, Net Income over the past three periods registered -$67.2 million, -$18.7 million, and -$68.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Armata Pharmaceuticals | 182.82 Mn | 158.82 Mn | - | -16.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -67.38 Mn |
| Mar 31, 2026 | -67.18 Mn |
| Dec 31, 2025 | -18.66 Mn |
| Sep 30, 2025 | -68.78 Mn |
| Jun 30, 2025 | -12.46 Mn |
| Mar 31, 2025 | -11.79 Mn |
| Dec 31, 2024 | -17.54 Mn |
| Sep 30, 2024 | -75.87 Mn |
| Jun 30, 2024 | -81.33 Mn |
| Mar 31, 2024 | -13.53 Mn |
| Dec 31, 2023 | -10.96 Mn |
| Sep 30, 2023 | -11.47 Mn |
| Jun 30, 2023 | -14.99 Mn |
| Mar 31, 2023 | -16.53 Mn |
| Dec 31, 2022 | -10.32 Mn |
| Sep 30, 2022 | -10.01 Mn |
| Jun 30, 2022 | -10.14 Mn |
| Mar 31, 2022 | -11.37 Mn |
| Dec 31, 2021 | -8.18 Mn |
| Sep 30, 2021 | -6.75 Mn |